News & Press

New Study Published in Journal of Drugs in Dermatology

New Study Published in Journal of Drugs in Dermatology Finds Artefill Effective in Treating Atrophic Acne Scars Ninety-Six Percent of Acne Scars Noticeably Improved Over Eight-Month Period SAN DIEGO, CA – October 7, 2010 – Suneva Medical, a privately-held aesthetic medical device company, today announced the publication of an open-label, single center, pilot study on …

New Study Published in Journal of Drugs in Dermatology Read More »

Suneva Medical Announces Canadian Approval of BellaFill®

SAN DIEGO, CA – June 29, 2011 – Suneva Medical, a privately-held aesthetic medical device company, today announced the expansion of its core aesthetics injectable business with approval from Health Canada to market BellafillTM, its long lasting dermal filler for nasolabial folds or smile line correction. In addition to offering patients a unique, long-lasting treatment, …

Suneva Medical Announces Canadian Approval of BellaFill® Read More »

Suneva Medical to Pursue Expanded Indications for Artefill® with Launch of Phase III Acne Scar Study

Suneva Medical to Pursue Expanded Indications for Artefill® with Launch of Phase III Acne Scar Study   SAN DIEGO, CA – January 11, 2012 – Suneva Medical, a privately-held aesthetic medical device company, today announced that it is launching a multi-center study to investigate the efficacy of Artefill for the treatment of acne scars. The …

Suneva Medical to Pursue Expanded Indications for Artefill® with Launch of Phase III Acne Scar Study Read More »

Suneva Medical Acquires Product Portfolio from Spear Pharmaceuticals

Suneva Medical Acquires Product Portfolio from Spear Pharmaceuticals Refissa Leads Suneva into the Topical Aesthetic Market SAN DIEGO, CA – May 21, 2012 – Suneva Medical, a privately-held aesthetics company, today announced that it has acquired an aesthetic product portfolio from Spear Pharmaceuticals (“Spear”). Under the terms of the agreement, Suneva will acquire worldwide rights …

Suneva Medical Acquires Product Portfolio from Spear Pharmaceuticals Read More »

Suneva Medical Completes Enrollment and Initial Treatment of Patients in Phase III Acne Scar Study

Suneva Medical Completes Enrollment and Initial Treatment of Patients in Phase III Acne Scar Study SAN DIEGO, CA – September 18, 2012 – Suneva Medical, Inc., a privately-held aesthetics company, today announced that it has completed the enrollment and initial treatment of patients in its Phase III acne scar study. Touch-up treatments are expected to …

Suneva Medical Completes Enrollment and Initial Treatment of Patients in Phase III Acne Scar Study Read More »

Suneva Medical Announces Results of Its Pivotal ArteFill® Acne Scar Study

Suneva Medical Announces Results of Its Pivotal ArteFill® Acne Scar Study ArteFill® study meets its primary efficacy endpoint in the treatment of acne scars Clinically and statistically significant results Company intends to file PMA supplement by the end of 2013 SAN DIEGO, CA – May 14, 2013 – Suneva Medical, Inc., a privately-held aesthetics company, …

Suneva Medical Announces Results of Its Pivotal ArteFill® Acne Scar Study Read More »

Important Safety Information

Bellafill®
Bellafill® is indicated for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. Patients who have had a positive reaction to the Bellafill® Skin Test, have a history of severe allergies, have known bovine collagen allergies, are allergic to lidocaine, have bleeding disorders or are prone to thick scar formation and/or excessive scarring should not receive Bellafill®. The safety of Bellafill® for use during pregnancy, breastfeeding, or in patients under 21 has not been established. You may experience temporary swelling, redness, pain, bruising, lumps/bumps, itching, and discoloration at the treatment site. These side effects are usually transient and typically resolve within 1–7 days. You may experience lumps/bumps/papules that may occur more than one month after injection and that may persist. Less common side effects include rash and itching more than 48 hours after treatment, persistent swelling or redness, lumps/bumps, acne, and increased sensitivity at treatment sites. Infrequently, granulomas may occur and may be treated by your licensed physician provider. Be sure to call your licensed provider immediately if you notice any unusual skin reactions around the treatment area. Based on the 5-year Post-Approval Study on nasolabial folds with 1,008 patients, long-term safety of Bellafill® for up to 5 years has been established.

PUREGRAFT
This product is certified as a medical device in the European Union under the Medical Device Directive 93/42/EEC by SGS CE0120, exclusively for the indication of autologous fat transfer. Other non-medical uses ascribed to this device such as aesthetic body contouring are not within the scope of CE certification, and users should be aware product performance and/or safety has not been evaluated by SGS for those purposes.

Suneva Medical HD PRP
REGULATORY STATUS: FDA-cleared 510(k) Class II medical device. Healeon HD PRP is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of peripheral blood at the patient point of care. The PRP is mixed with autograft and/orallograft bone prior to application to a bony defect for improving handling characteristics. 510(k) number: BK170136

For more safety information, please consult with your physician and the patient labeling that can be found by visiting our website www.bellafill.com.
Toll-free call (U.S. & Canada): 844-Bellafill (844-235-5234).
Local calls: 858-550-9999. International calls: ++ 858-550-9999.